GSK reports positive data for experimental blood cancer drug

The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

(Reuters) – GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer. The DREAMM-1 study of patients with relapsed/refractory multiple myeloma confirmed the potential effectiveness of the medicine, GSK said. “We are aggressively advancing this potential new medicine and […]

Continue reading this article with a Fiji Times online membership.

More Stories